1. Home
  2. VALN vs STRO Comparison

VALN vs STRO Comparison

Compare VALN & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.17

Market Cap

536.9M

Sector

Health Care

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$26.85

Market Cap

524.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALN
STRO
Founded
2012
2003
Country
France
United States
Employees
N/A
133
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.9M
524.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VALN
STRO
Price
$5.17
$26.85
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$15.50
$31.33
AVG Volume (30 Days)
31.5K
303.0K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$93.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.06
$0.67
52 Week High
$12.25
$43.85

Technical Indicators

Market Signals
Indicator
VALN
STRO
Relative Strength Index (RSI) 36.83 42.69
Support Level $5.11 $23.53
Resistance Level $6.60 $27.96
Average True Range (ATR) 0.25 2.87
MACD -0.05 -0.33
Stochastic Oscillator 10.45 40.44

Price Performance

Historical Comparison
VALN
STRO

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: